Lantern Pharma Inc. (LTRN) 10-Year Financial Performance & Capital Metrics

LTRN • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesDiagnostics & Immune Monitoring

AboutLantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.Show more

Revenue $0
EBITDA -$22M -25.4%
Net Income -$21M -30.2%
EPS (Diluted) -1930.92 -131255.1%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -66.93% -103.3%
ROIC -100.6% -42.9%
Debt/Equity 0.01 +100.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM0.9%

EPS CAGR

10Y-

5Y-

3Y-

TTM1.69%

ROCE

10Y Avg-145.06%

5Y Avg-43.08%

3Y Avg-43.63%

Latest-71.42%

Peer Comparison

Diagnostics & Immune Monitoring

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TECHBio-Techne Corporation	10.9B	69.96	152.09	5.23%	6.41%	3.97%	2.35%	0.23
SPRYARS Pharmaceuticals, Inc.	1.1B	11.09	142.00	2970.63%	-56.06%	-54.21%	1.18%	0.00
VCYTVeracyte, Inc.	3.24B	41.00	132.26	23.46%	6.12%	2.41%	1.97%	0.04
CSBRChampions Oncology, Inc.	99.56M	7.17	21.73	13.54%	4.32%	59.65%	7.03%	1.62
MDXGMiMedx Group, Inc.	851.59M	5.75	20.54	8.52%	10.38%	17.09%	7.58%	0.13
LTRNLantern Pharma Inc.	39.26M	3.51	-0.00			-197.36%		0.01
SEERSeer, Inc.	107.44M	1.91	-1.37	-8.13%	-486.02%	-29.19%		0.08
IMDXInsight Molecular Diagnostics Inc.	189.76M	6.62	-1.42	25.15%	-13.81%	-14.81%

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-
Cost of Goods Sold+	-2.54K	1.63K	0	0	0	174.84K	0
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	2.54K	-1.63K	0	0	0	-174.84K	0
Gross Margin %	-	-	-	-	-	-	-
Gross Profit Growth %	-	-1.64%	1%	-	-	-	1%
Operating Expenses+	1.73M	2.43M	5.91M	12.59M	14.43M	17.7M	22.22M
OpEx % of Revenue	-	-	-	-	-	-	-
Selling, General & Admin	1.15M	1.48M	3.66M	5.02M	5.83M	5.98M	6.09M
SG&A % of Revenue	-	-	-	-	-	-	-
Research & Development	572.1K	953.18K	2.24M	7.57M	8.6M	11.89M	16.13M
R&D % of Revenue	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	-174.84K	0
Operating Income+	-1.73M	-2.43M	-5.91M	-12.59M	-14.43M	-17.88M	-22.22M
Operating Margin %	-	-	-	-	-	-	-
Operating Income Growth %	-	-0.41%	-1.43%	-1.13%	-0.15%	-0.24%	-0.24%
EBITDA+	-1.73M	-2.43M	-5.9M	-12.58M	-14.42M	-17.7M	-22.2M
EBITDA Margin %	-	-	-	-	-	-	-
EBITDA Growth %	-	-0.4%	-1.43%	-1.13%	-0.15%	-0.23%	-0.25%
D&A (Non-Cash Add-back)	-2.54K	1.63K	3.39K	6.76K	10.08K	174.84K	17.28K
EBIT	-1.73M	-2.43M	-5.91M	-12.59M	-14.43M	-15.96M	-22.22M
Net Interest Income+	0	0	0	67.93K	0	765.39K	742.36K
Interest Income	0	0	0	67.93K	204.35K	765.39K	742.36K
Interest Expense	0	0	0	0	204.35K	0	0
Other Income/Expense	0	0	0	228.48K	172.81K	1.92M	1.44M
Pretax Income+	-1.73M	-2.43M	-5.91M	-12.36M	-14.26M	-15.96M	-20.78M
Pretax Margin %	-	-	-	-	-	-	-
Income Tax+	2.54K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%
Net Income+	-1.73M	-2.43M	-5.91M	-12.36M	-14.26M	-15.96M	-20.78M
Net Margin %	-	-	-	-	-	-	-
Net Income Growth %	-	-0.41%	-1.43%	-1.09%	-0.15%	-0.12%	-0.3%
Net Income (Continuing)	-1.73M	-2.43M	-5.91M	-12.36M	-14.26M	-15.96M	-20.78M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-0.28	-0.39	-0.95	-1.13	-1.31	-1.47	-1930.92
EPS Growth %	-	-0.39%	-1.44%	-0.19%	-0.16%	-0.12%	-1312.55%
EPS (Basic)	-0.28	-0.39	-0.95	-1.13	-1.31	-1.47	-1930.92
Diluted Shares Outstanding	6.22M	6.27M	6.22M	10.9M	10.85M	10.84M	10.76M
Basic Shares Outstanding	6.22M	6.27M	6.22M	10.9M	10.85M	10.84M	10.76M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	445.16K	1.23M	20.24M	72.72M	58.72M	43.34M	25.25M
Cash & Short-Term Investments	445.16K	1.23M	19.23M	70.73M	55.2M	41.3M	24.01M
Cash Only	445.16K	1.23M	19.23M	51.52M	37.2M	21.94M	7.51M
Short-Term Investments	0	0	0	19.2M	17.99M	19.36M	16.5M
Accounts Receivable	0	0	0	181K	0	860K	0
Days Sales Outstanding	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	0	0	0	378.95K	541.18K	745.65K	1.23M
Total Non-Current Assets+	4.67K	199.76K	122.71K	1.23M	113.58K	306.29K	324.16K
Property, Plant & Equipment	4.67K	8.76K	21.51K	216.19K	95.69K	280.42K	287.43K
Fixed Asset Turnover	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	1M	0	0	0
Other Non-Current Assets	0	191K	101.2K	17.89K	17.89K	25.87K	36.74K
Total Assets+	449.83K	1.43M	20.36M	73.95M	58.84M	43.65M	25.57M
Asset Turnover	-	-	-	-	-	-	-
Asset Growth %	-	2.18%	13.21%	2.63%	-0.2%	-0.26%	-0.41%
Total Current Liabilities+	651.63K	489.29K	552.34K	2.33M	2.8M	2.68M	4.33M
Accounts Payable	97.63K	478.29K	432.34K	2.17M	0	942.21K	0
Days Payables Outstanding	-14.01K	107.3K	-	-	-	1.97K	-
Short-Term Debt	0	0	0	152.06K	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0
Other Current Liabilities	535K	2K	120K	0	2.75M	1.56M	4.14M
Current Ratio	0.68x	2.52x	36.64x	31.26x	20.99x	16.18x	5.83x
Quick Ratio	0.68x	2.52x	36.64x	31.26x	20.99x	16.18x	5.83x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	108.5K	52.89K	0	61.5K	52.84K
Long-Term Debt	0	0	108.5K	0	0	0	0
Capital Lease Obligations	0	0	0	52.89K	0	61.5K	52.84K
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0
Total Liabilities	651.63K	489.29K	660.84K	2.38M	2.8M	2.74M	4.38M
Total Debt+	0	0	108.5K	204.95K	52.89K	234.47K	243.66K
Net Debt	-445.16K	-1.23M	-19.12M	-51.32M	-37.15M	-21.7M	-7.27M
Debt / Equity	-	-	0.01x	0.00x	0.00x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-70.63x	-	-
Total Equity+	-201.8K	943.28K	19.7M	71.57M	56.04M	40.91M	21.19M
Equity Growth %	-	5.67%	19.88%	2.63%	-0.22%	-0.27%	-0.48%
Book Value per Share	-0.03	0.15	3.17	6.56	5.16	3.77	1.97
Total Shareholders' Equity	-201.8K	943.28K	19.7M	71.57M	56.04M	40.91M	21.19M
Common Stock	11.37K	11.37K	622	1.11K	1.09K	1.07K	1.08K
Retained Earnings	-4.32M	-6.75M	-12.66M	-25.02M	-39.28M	-55.24M	-76.03M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	-92.69K	-371.39K	-107.46K	153.99K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.27M	-2.13M	-5.65M	-10.59M	-12.77M	-14.35M	-17.81M
Operating CF Margin %	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.67%	-1.66%	-0.87%	-0.21%	-0.12%	-0.24%
Net Income	-1.73M	-2.43M	-5.91M	-12.36M	-14.26M	-15.96M	-20.78M
Depreciation & Amortization	-2.54K	1.63K	3.39K	6.76K	10.08K	14.62K	190.49K
Stock-Based Compensation	185.6K	0	1.19M	961.54K	1.19M	1.07M	0
Deferred Taxes	0	0	0	0	0	0	0
Other Non-Cash Items	-76.32K	117.76K	0	203.22K	906.49K	-5.17K	549.36K
Working Capital Changes	271.84K	180.88K	-939.06K	599.96K	-611.86K	538.02K	2.23M
Change in Receivables	186.6K	0	0	0	0	0	-175.72K
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	70.24K	372.66K	0	0	0	0	1.64M
Cash from Investing+	5.34K	-5.72K	-16.14K	-19.53M	179.27K	-930.21K	3.37M
Capital Expenditures	0	-5.72K	-16.14K	-15.5K	-27.84K	-18.73K	-12.6K
CapEx % of Revenue	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	5.34K	0	0	0	0	0	0
Cash from Financing+	535K	2.92M	23.66M	63.42M	-2.18M	-500K	66.71K
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	535K	0	-28.94M	-4.64M	2.78M	0	0
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-1.27M	-2.13M	-5.67M	-10.61M	-12.8M	-14.37M	-17.83M
FCF Margin %	-	-	-	-	-	-	-
FCF Growth %	-	-0.68%	-1.66%	-0.87%	-0.21%	-0.12%	-0.24%
FCF per Share	-0.20	-0.34	-0.91	-0.97	-1.18	-1.32	-1.66
FCF Conversion (FCF/Net Income)	0.74x	0.88x	0.96x	0.86x	0.90x	0.90x	0.86x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-654.95%	-57.24%	-27.09%	-22.35%	-32.93%	-66.93%
Return on Invested Capital (ROIC)	-	-	-3063.17%	-90.67%	-55.31%	-70.4%	-100.6%
Debt / Equity	-	-	0.01x	0.00x	0.00x	0.01x	0.01x
Interest Coverage	-	-	-	-	-70.63x	-	-
FCF Conversion	0.74x	0.88x	0.96x	0.86x	0.90x	0.90x	0.86x

Frequently Asked Questions

Growth & Financials

Lantern Pharma Inc. (LTRN) grew revenue by 0.0% over the past year. Growth has been modest.

Lantern Pharma Inc. (LTRN) reported a net loss of $18.9M for fiscal year 2024.

Dividend & Returns

Lantern Pharma Inc. (LTRN) has a return on equity (ROE) of -66.9%. Negative ROE indicates the company is unprofitable.

Lantern Pharma Inc. (LTRN) had negative free cash flow of $16.9M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener